ClinicalTrials.gg
RecruitingNCT06284590INTACT/MeRCIUpdated Sep 2, 2026

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

A Phase 2 interventional study of L19IL2 and L19TNF in Melanoma Stage III and Melanoma Stage IV, sponsored by Philogen S.p.A.. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Philogen S.p.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 71 under way, 20 of them phase 3. Melanoma · Germany.

Planned enrollment
125th of 249
162 · median 162
Started
2024
with 12 others
Phase 2
80 of 284
6 open now
Primary completion
2028-07
later than 54 of 70 live
Registered
260th of 284
by date
Lead sponsor
5 of 284
Philogen S.p.A.

Among the 284 studies in Melanoma with a site in Germany, this one is the 125th largest by planned enrollment of the 249 interventional ones that give a count, is one of 13 that started in 2024, is one of 80 in phase 2, reaches primary completion later than 54 of the 70 other live ones, and was the 260th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.

Read the detailed description

The present study is a randomized, open-label, three-arm, parallel phase 2 study. A Simon two-stage design for the study of the efficacy of intralesional therapy with L19IL2 or L19TNF or L19IL2/L19TNF in combination with systemic anti-PD1 pembrolizumab immunotherapy will be used.

In the study, 162 patients will be randomized in a 1:1:1 ratio to receive:

i) systemic pembrolizumab in combination with intralesional L19IL2 (Arm 1) or ii) systemic pembrolizumab in combination with intralesional L19TNF (Arm 2) or iii) systemic pembrolizumab in combination with intralesional L19IL2/L19TNF (Arm 3).

This is an open-label study, so there is no blinding.

The study consists of a two-week screening period, followed by a 4-weeks open-label intralesional treatment period with immunocytokines (ICKs) either L19IL2, L19TNF or L19IL2/L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with ICKs, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.

Follow-up for progression free survival will be performed up to 2 years after first intralesional treatment. Survival information will be collected up to 3 years after first intralesional treatment.

A safety run-in will be performed on the first 12 patients enrolled in each arm of the study. Patients will be evaluated during the first 21-days cycle for the occurrence of the treatment-related adverse events. All toxicities will be graded using NCI CTCAE Version 5.0 based on the investigator assessment to be possibly, probably, or definitely related to study treatment administration.

In addition to this, safety information collected will be routinely reviewed by the Data and Safety Monitoring Board (DSMB) in order to identify possible safety concerns.

The primary objective of the study is to demonstrate the efficacy of intralesional treatment with ICKs, in combination with systemic anti-PD1 immunotherapy with pembrolizumab, to induce objective responses in advanced melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors.

Primary endpoint of the study is the Confirmed Objective Response Rate (ORR = CR + PR) in all three arms over a period of up to 2 years after first intralesional treatment, according to RECIST v1.1 criteria in each arm of the study. The primary analysis will be performed in the Intention-to-Treat population (ITT).

For each of the three treatment arms, secondary objectives include efficacy and safety of intralesional treatment with ICKs.

The secondary endpoints include:

  • Best overall response (BOR; the best overall response is the best response recorded from the start of the treatment until disease progression/recurrence according to RECIST v1.1 criteria)
  • Duration of response (DoR)
  • Pathological response of one target lesion injected with ICKs at 18 weeks after first treatment
  • Confirmed ORR over a period of up to 2 years after first intralesional treatment, according to iRECIST (see Appendix 1) and itRECIST [1] criteria in each arm of the study
  • Progression-free survival (PFS) from time of randomization
  • Overall survival (OS) from randomization
  • Number, frequency and grading of adverse events (AEs) and serious adverse events (SAEs) related to intralesional therapy with ICKs in combination with systemic anti-PD1 therapy

End of treatment: last day of anti-PD1 therapy or until progression or unacceptable toxicity.

End of study: corresponds to the last patient last visit (LPLV).

03

Conditions studied

  • Melanoma Stage III
  • Melanoma Stage IV

Browse trials for

Keywords

  • anti-PD1 checkpoint inhibitors
  • Melanoma Stage III
  • Melanoma Stage IV
  • pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant (or legally acceptable representative if applicable) provides written for the trial.
  2. Be > or = 18 years of age on day of signing informed consent.
  3. Participant with or cytologically confirmed diagnosis of unresectable melanoma at stage III B, C, D or IV M1a (AJCC 8th ed.). Patients with Stage IVM1b, M1c and M1d oligometastatic disease [up to 10 visceral lesions in aggregate including lung, liver, bone or brain, with or without lymph node involvement], are eligible.

    However, patients with symptomatic or rapidly enlarging/bleeding brain lesions are excluded. Patients with acral lentiginous melanoma are eligible as well. Detailed information about prior therapies and burden of disease at study entry must be available.

  4. Patients must have confirmed primary resistance to or acquired resistance on treatment with an anti-PD1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:

    1. Has received at least 2 doses of an approved anti-PD-1/L1 mAb.
    2. Has demonstrated disease progression (PD) after PD-1/L1 as defined by v1.1. The initial evidence of PD is to be confirmed by a second assessment no less than four weeks from the date of the first documented PD, in the absence of rapid clinical progression.
    3. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-1/L1 mAb.

    c.i. Progressive disease is determined according to . c.ii. This determination is made by the investigator. Once PD is confirmed, the initial date of PD documentation will be considered the date of disease progression.

  5. Patients harboring the BRAF mutation who received BRAF/MEK inhibition (or declined BRAF/MEK inhibitors) and received thereafter anti-PD1 therapy showing resistance to such immunotherapy are eligible to the study.
  6. Eligible subjects must have (according to RECIST v1.1) as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Eligible subjects must be candidates for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal metastatic melanoma lesion (≥ 5 mm in longest diameter) or multiple injectable lesions that in aggregate have a diameter of ≥ 5 mm.
  7. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP)
    2. A WOCBP who agrees to follow guidance during the treatment period and for at least 120 days after the last dose of study treatment. WOCBP must be using for the time period indicated highly effective contraception methods. WOCBP and effective contraception methods are defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated at the safety visit (only WOCBP).
  8. Have provided sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.

    Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut (details pertaining to tumor tissue submission can be found in the Procedures Manual).

  9. Have an (ECOG) performance status of 0 to 1.
  10. Have adequate organ function. Specimens must be collected within 14 days prior to the start of study treatment.
  11. Be able to provide a core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy at Screening. In addition, participants may provide additional biopsy at Week 18 and at the time of discontinuation due to progression.
  12. Documented negative test for , and . For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (e.g. anti-HBsAg and/or anti-HBc Ab) a negative serum HBV-DNA test is also required.
  13. All acute toxic effects (excluding alopecia and vitiligo) of any prior therapy must have resolved to National Cancer Institute (NCI) (CTCAE) (v. 5.0) Grade ≤ 1 or baseline unless otherwise specified above.

    Note: Participants with ≤Grade 2 neuropathy may be eligible. Participants with endocrinerelated AEs Grade ≤2 requiring treatment or hormone replacement may be eligible. Note: If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery before starting study intervention.

  14. Full resolution of checkpoint blockade therapy-related adverse effects (including immunerelated adverse effects) and no treatment for these AEs for at least 4 weeks before the time of enrollment.
  15. No history of severe immune related adverse effects from prior given immune checkpoint blockade therapy (CTCAE Grade 4; CTCAE Grade 3 requiring treatment >4 weeks).
  16. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration. In addition, male participant must refrain from sperm donation during the treatment period.
  17. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with more than 10 distant melanoma lesions in lung, liver, bone or brain combined. Patients with symptomatic or rapidly enlarging/bleeding brain lesions are excluded.
  2. Uveal melanoma or mucosal melanoma or melanoma with unknown primary.
  3. A who has a positive urine pregnancy test (within 72 hours) prior to treatment.

    If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  4. Has received prior therapy with an , anti-PD-L1, and was discontinued from that treatment due to a Grade 3 or higher irAE.
  5. Has received prior systemic anti-cancer therapy including agents or has used an investigational device within 4 weeks prior to the first dose of study treatment.

    Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

  6. Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis.

    Note: Participants must have recovered from all radiation-related toxicities andnot require . A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.

  7. Has undergone prior hematopoietic stem cell transplantation within the last 5 years. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of ).
  8. Has had an allogeneic tissue/solid organ transplant.
  9. Has received live live or within 30 days prior to the first dose of study treatment and while participating in the study. Note: Killed vaccines are allowed.

    Note: Any licensed COVID-19 vaccine (including for Emergency use) in a particular country is allowed in the study as long as they are mRNA vaccines, adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.

    Investigational vaccines (i.e., those not licensed or approved for Emergency Use) are not allowed.

  10. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study drug.
  11. Has a known additional that is progressing or has required active treatment within the past two (2) years.

    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder tumors (Ta, Tis \& T1), second primary melanoma in situ, or carcinoma in situ, that have undergone potentially curative therapy are not excluded.

  12. Has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  13. Has severe (≥Grade 3) to pembrolizumab and/or any of its , or to (immuno)cytokines IL2, TNF and/or any of its excipients
  14. Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  15. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  16. Has an active infection requiring systemic therapy.
  17. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  18. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  19. Previous enrolment and randomization in this same study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Systemic pembrolizumab in combination with intralesional L19IL2 (Arm 1)

    Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.

    Drug: L19IL2 · Drug: KEYTRUDA®

  • Experimental
    Systemic pembrolizumab in combination with intralesional L19TNF (Arm 2)

    Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.

    Drug: L19TNF · Drug: KEYTRUDA®

  • Experimental
    Systemic pembrolizumab in combination with intralesional L19IL2/L19TNF (Arm 3)

    Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2/L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2/L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.

    Drug: L19IL2/L19TNF · Drug: KEYTRUDA®

Interventions

  • DrugL19IL2

    Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.

    Also known as: bifikafusp alfa

  • DrugL19TNF

    Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.

    Also known as: onfekafusp alfa

  • DrugL19IL2/L19TNF

    Drug page: Daromun

    Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.

    Also known as: Daromun

  • KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.

    Also known as: pembrolizumab

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR)

    Objective Response Rate (ORR = CR + PR) in all three arms to demonstrate the efficacy of intralesional treatment with immunocytokines (L19IL2, or L19TNF, or L19IL2/L19TNF), in combination with the systemic anti-PD1 pembrolizumab, to induce objective responses in advanced melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors. The primary analysis will be performed in the Intention-to-Treat population (ITT). Assessed during Tumor Assessment (TA) visits.

    Time frame: Evaluated over a period of up to 2 years after first intralesional treatment. TA visits will be performed at week 12, 18, 24, 36, 48, 64, 80 and 96 after first intralesional treatment or until confirmed progression or death, whichever occurs first

Secondary outcomes

  1. Best overall response (BOR)

    Best response recorded from the start of the treatment until disease progression/recurrence after first treatment according to RECIST v1.1 criteria

    Time frame: From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 96 Weeks

  2. Duration of Response (DoR)

    Time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. DoR will be summarized descriptively using Kaplan-Meier medians and quartiles.

    Time frame: From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 Months

  3. Pathological response

    Histopathological analysis will be performed on biopsies obtained at baseline and at Week 18 for one target injected lesions. This is to determine: * Confirmation of melanoma metastasis( Biopsy at baseline) * Presence of residual tumor cells (%, biopsy at week 18), * Presence of Necrosis % (biopsy at week 18), * Presence of melanosis/fibrosis % (biopsy at weeks 18 after first treatment)

    Time frame: At 18 weeks after first treatment

  4. Confirmed ORR

    Confirmed ORR over a period of up to 2 years after first intralesional treatment according to iRECIST and itRECIST criteria in each arm of the study

    Time frame: From date of first administration, after a period of up to 2 years

  5. Progression-free survival (PFS)

    Difference between date of randomization and the date of progression according to RECIST v. 1.1 criteria or death

    Time frame: From the date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 96 Weeks

  6. Overall survival (OS)

    Difference between date of randomization and the date of death for any cause

    Time frame: From the date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 96 Weeks

  7. Adverse Events (AEs) and Serious Adverse Event (SAEs)

    Percentage of Patients in Each Treatment Group with Drug-Related Adverse Events, Serious Adverse Event (SAEs)

    Time frame: From date of ICF signature until first follow-up visit (Week 12). Subsequently only AEs and SAEs (and related medications or procedures) that were judged as drug or study related will be recorded, up to week 96

  8. Drug-Induced Liver Injury (DILI)

    Number of patients with Drug-Induced Liver Injury (DILI)

    Time frame: From date of ICF signature until first follow-up visit (Week 12). Subsequently only DILI that were judged as drug or study related will be recorded, up to week 96

  9. Adverse Events of Special Interest (AESI)

    Number of patients with Adverse Events of Special Interest (AESI)

    Time frame: From date of ICF signature until first follow-up visit (Week 12). Subsequently only AESI that were judged as drug or study related will be recorded, up to week 96

  10. Immune-Related Adverse Events (IRAEs)

    Number of patients with Immune-Related Adverse Events (IRAEs)

    Time frame: From date of ICF signature until first follow-up visit (Week 12). Subsequently only IRAEs that were judged as drug or study related will be recorded, up to week 96

  11. Abnormal hematology laboratory tests results: Red Blood Cells

    Number of participants with abnormal hematology laboratory tests results: red blood cells; Millions/microliter (M/mcL)

    Time frame: From the screening to the last visit (Week 103)

  12. Abnormal hematology laboratory tests results: Neutrophil, White Blood Cells, Platelet, Differential

    Number of participants with abnormal hematology laboratory tests results: Count of absolute neutrophil (ANC), White Blood cells (WBC), Platelet, Differential; thousands/microliter (K/mcL)

    Time frame: From the screening to the last visit (Week 103)

  13. Abnormal hematology laboratory tests results: Hematocrit

    Number of participants with abnormal hematology laboratory tests results: Hematocrit; percent (%)

    Time frame: From the screening to the last visit (Week 103)

  14. Abnormal hematology laboratory tests results: Hemoglobin

    Number of participants with abnormal hematology laboratory tests results: Hemoglobin; grams/deciliter (g/dL)

    Time frame: From the screening to the last visit (Week 103)

  15. Abnormal serum chemistry laboratory tests results: Creatinine, Blood Urea Nitrogen or Urea, Uric acid, Calcium, Glucose, Phosphorus, Magnesium

    Number of participants with abnormal serum chemistry laboratory tests results: Creatinine, Blood Urea Nitrogen or Urea, Uric acid, Calcium, Glucose, Phosphorus, Magnesium; milligrams/deciliter (mg/dL)

    Time frame: From the screening to the last visit (Week 103)

  16. Abnormal serum chemistry laboratory tests results: Potassium, Sodium, Chloride

    Number of participants with abnormal serum chemistry laboratory tests results: Potassium, Sodium, Chloride; milliequivalents/liter (mEq/L)

    Time frame: From the screening to the last visit (Week 103)

  17. Abnormal serum chemistry laboratory tests results: Total proteins, Albumin

    Number of participants with abnormal serum chemistry laboratory tests results: Total proteins, Albumin; grams/deciliter (g/dL)

    Time frame: From the screening to the last visit (Week 103)

  18. Abnormal serum chemistry laboratory tests results: Lactate dehydrogenase (LDH)

    Number of participants with abnormal serum chemistry laboratory tests results: Lactate dehydrogenase (LDH); units/liter (U/L)

    Time frame: From the screening to the last visit (Week 103)

  19. Abnormal serum chemistry laboratory tests results: Adrenocorticotropic Hormone (ACTH)

    Number of participants with abnormal serum chemistry laboratory tests results: Adrenocorticotropic Hormone (ACTH); picograms/milliliter (pg/ml)

    Time frame: From the screening to the last visit (Week 103)

  20. Abnormal coagulation laboratory tests results: Prothrombin Time PT or PT INR, PTT or aPTT

    Number of participants with abnormal coagulation laboratory tests results: Prothrombin Time PT or PT INR, PTT or aPTT; seconds (sec)

    Time frame: From the screening to the last visit (Week 103)

  21. Abnormal body temperature

    Number of participants with abnormal body temperature (degree centigrade)

    Time frame: From the screening to the last visit (Week 103)

  22. Abnormal blood pressure

    Number of participants with abnormal blood pressure: Systolic and diastolic blood pressure (after 3 minutes in sitting position); mmHg

    Time frame: From the screening to the last visit (Week 103)

  23. Abnormal Electrocardiogram (ECG) readings

    Number of participants with abnormal Electrocardiogram (ECG) readings: Heart rate, standard intervals (PR, QRS, QT, and QTc) and any observed abnormality; millisecond

    Time frame: At the screening visit, at Visit 6 (week 5) and at Visit 12 (week 18)

  24. Abnormal Echocardiogram (ECHO) readings

    Number of participants with abnormal Echocardiogram (ECHO) readings: Morphological and functional aspects of the heart. Left Ejection Fraction (LVEF) is determined; percentage %

    Time frame: At the screening visit, at Visit 6 (week 5) and at Visit 12 (week 18)

  25. Abnormal physical examination results

    Number of participants with abnormal physical examination results

    Time frame: From the screening to first follow up visit

  26. Concomitant medication usage

    Concomitant medication usage

    Time frame: From the screening and throughout study

  27. Human anti-fusion protein antibodies (HAFA)

    Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF

    Time frame: At weeks 1, 2 and 12

07

Study locations

5 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2028, 48 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 48 months is above that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 29, 2024
StartActual
Jul 12, 2024
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06284590
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Jul 12, 2024
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Sheila Dakhel Plaza, PhD
Contact
sheila.dakhel@philochem.ch
+41 (0) 43 544 88 02
Concetta Aulicino
Contact
regulatory@philogen.com
+39 057717816
Danielle Bello
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darleukin · Onfekafusp alfa · Daromun

Start the discussion